IMPACT OF ECONOMIC CRISIS ON THE MANAGEMENT OF HEMOPHILIA PATIENTS IN GREECE
(Abstract release date: 05/19/16)
EHA Library. Economou M. 06/09/16; 135005; PB2105
Assoc. Prof. Marina Economou
Contributions
Contributions
Abstract
Abstract: PB2105
Type: Publication Only
Background
Economic crisis has had a major impact on public health in Greece during the last years, negatively affecting both ability for health insurance coverage and availability of medical services. As all patients suffering from chronic illnesses, hemophilia patients have had to face difficulties resulting from the austerity measures.
Aims
Purpose of the present retrospective study was to evaluate the impact of economic crisis on management of hemophilia patients for the 6 year crisis period (January 2010 - December 2015) in a single pediatric institution.
Methods
The study included hemophilia A patients followed at the Pediatric Center for Bleeding Disorders of Aristotle University of Thessaloniki, one of the two pediatric hemophilia centers in Greece. Data were recorded 23 for patients with severe hemophilia (FVIII < 1%) or moderate hemophilia (FVIII 1-5%) presenting with a severe bleeding phenotype. Patients with inhibitor presence were excluded from the study. A subgroup consisting of 12 patients on regular prophylaxis throughout the studied years was separately evaluated. Data assessed included annual factor consumption (IU/kg) and annual cost for the years studied. The prices for factor concentrates were obtained from the Greek National Organization for Medicines. Changes in patients’ family working status and subsequent insurance coverage were also recorded.
Results
Mean age of patients was 11.3 year (range 2-19 years). The mean annual factor consumption did not significantly differ between the onset of crisis and the following years in both groups studied (i.e. total and regular prophylaxis patients). Similarly, the average annual cost per patient did not significantly change during the crisis years for either group. In specific, mean factor consumption for the whole group at starting and closing years was 334.167 ± 227.536 U/KG and 318.235 ± 105.92 U/KG, respectively, with respective mean annual costs 114,864 ± 82,097 and 108,989 ± 62,862 euros. For the regular prophylaxis group mean factor consumption for starting and closing years was 350.16± 268482 U/KG and 318.235 ± 105.92 U/KG, respectively, with mean annual costs 114,187 ± 97,772 and 134,61 ± 54,159 euros. With regards to employment and insurance ability, one patient lost coverage due to parents' unemployment. However, Social Security provided cost-free factor administration, enabling patient to continue his treatment. The only change recorded between crisis onset and following years was a significant increase in number of hospital visits required in order to have access to factor administration, as a result of limited amount of factor administered by the hospital at each visit for home treatment.
Conclusion
Although Greece has seriously suffered during the last years because of the economic crisis, provision for health has managed to survive - at least for hemophilia patients. Albeit, without some cost on the patients’ part…
Session topic: E-poster
Keyword(s): Children, Hemophilia A
Type: Publication Only
Background
Economic crisis has had a major impact on public health in Greece during the last years, negatively affecting both ability for health insurance coverage and availability of medical services. As all patients suffering from chronic illnesses, hemophilia patients have had to face difficulties resulting from the austerity measures.
Aims
Purpose of the present retrospective study was to evaluate the impact of economic crisis on management of hemophilia patients for the 6 year crisis period (January 2010 - December 2015) in a single pediatric institution.
Methods
The study included hemophilia A patients followed at the Pediatric Center for Bleeding Disorders of Aristotle University of Thessaloniki, one of the two pediatric hemophilia centers in Greece. Data were recorded 23 for patients with severe hemophilia (FVIII < 1%) or moderate hemophilia (FVIII 1-5%) presenting with a severe bleeding phenotype. Patients with inhibitor presence were excluded from the study. A subgroup consisting of 12 patients on regular prophylaxis throughout the studied years was separately evaluated. Data assessed included annual factor consumption (IU/kg) and annual cost for the years studied. The prices for factor concentrates were obtained from the Greek National Organization for Medicines. Changes in patients’ family working status and subsequent insurance coverage were also recorded.
Results
Mean age of patients was 11.3 year (range 2-19 years). The mean annual factor consumption did not significantly differ between the onset of crisis and the following years in both groups studied (i.e. total and regular prophylaxis patients). Similarly, the average annual cost per patient did not significantly change during the crisis years for either group. In specific, mean factor consumption for the whole group at starting and closing years was 334.167 ± 227.536 U/KG and 318.235 ± 105.92 U/KG, respectively, with respective mean annual costs 114,864 ± 82,097 and 108,989 ± 62,862 euros. For the regular prophylaxis group mean factor consumption for starting and closing years was 350.16± 268482 U/KG and 318.235 ± 105.92 U/KG, respectively, with mean annual costs 114,187 ± 97,772 and 134,61 ± 54,159 euros. With regards to employment and insurance ability, one patient lost coverage due to parents' unemployment. However, Social Security provided cost-free factor administration, enabling patient to continue his treatment. The only change recorded between crisis onset and following years was a significant increase in number of hospital visits required in order to have access to factor administration, as a result of limited amount of factor administered by the hospital at each visit for home treatment.
Conclusion
Although Greece has seriously suffered during the last years because of the economic crisis, provision for health has managed to survive - at least for hemophilia patients. Albeit, without some cost on the patients’ part…
Session topic: E-poster
Keyword(s): Children, Hemophilia A
Abstract: PB2105
Type: Publication Only
Background
Economic crisis has had a major impact on public health in Greece during the last years, negatively affecting both ability for health insurance coverage and availability of medical services. As all patients suffering from chronic illnesses, hemophilia patients have had to face difficulties resulting from the austerity measures.
Aims
Purpose of the present retrospective study was to evaluate the impact of economic crisis on management of hemophilia patients for the 6 year crisis period (January 2010 - December 2015) in a single pediatric institution.
Methods
The study included hemophilia A patients followed at the Pediatric Center for Bleeding Disorders of Aristotle University of Thessaloniki, one of the two pediatric hemophilia centers in Greece. Data were recorded 23 for patients with severe hemophilia (FVIII < 1%) or moderate hemophilia (FVIII 1-5%) presenting with a severe bleeding phenotype. Patients with inhibitor presence were excluded from the study. A subgroup consisting of 12 patients on regular prophylaxis throughout the studied years was separately evaluated. Data assessed included annual factor consumption (IU/kg) and annual cost for the years studied. The prices for factor concentrates were obtained from the Greek National Organization for Medicines. Changes in patients’ family working status and subsequent insurance coverage were also recorded.
Results
Mean age of patients was 11.3 year (range 2-19 years). The mean annual factor consumption did not significantly differ between the onset of crisis and the following years in both groups studied (i.e. total and regular prophylaxis patients). Similarly, the average annual cost per patient did not significantly change during the crisis years for either group. In specific, mean factor consumption for the whole group at starting and closing years was 334.167 ± 227.536 U/KG and 318.235 ± 105.92 U/KG, respectively, with respective mean annual costs 114,864 ± 82,097 and 108,989 ± 62,862 euros. For the regular prophylaxis group mean factor consumption for starting and closing years was 350.16± 268482 U/KG and 318.235 ± 105.92 U/KG, respectively, with mean annual costs 114,187 ± 97,772 and 134,61 ± 54,159 euros. With regards to employment and insurance ability, one patient lost coverage due to parents' unemployment. However, Social Security provided cost-free factor administration, enabling patient to continue his treatment. The only change recorded between crisis onset and following years was a significant increase in number of hospital visits required in order to have access to factor administration, as a result of limited amount of factor administered by the hospital at each visit for home treatment.
Conclusion
Although Greece has seriously suffered during the last years because of the economic crisis, provision for health has managed to survive - at least for hemophilia patients. Albeit, without some cost on the patients’ part…
Session topic: E-poster
Keyword(s): Children, Hemophilia A
Type: Publication Only
Background
Economic crisis has had a major impact on public health in Greece during the last years, negatively affecting both ability for health insurance coverage and availability of medical services. As all patients suffering from chronic illnesses, hemophilia patients have had to face difficulties resulting from the austerity measures.
Aims
Purpose of the present retrospective study was to evaluate the impact of economic crisis on management of hemophilia patients for the 6 year crisis period (January 2010 - December 2015) in a single pediatric institution.
Methods
The study included hemophilia A patients followed at the Pediatric Center for Bleeding Disorders of Aristotle University of Thessaloniki, one of the two pediatric hemophilia centers in Greece. Data were recorded 23 for patients with severe hemophilia (FVIII < 1%) or moderate hemophilia (FVIII 1-5%) presenting with a severe bleeding phenotype. Patients with inhibitor presence were excluded from the study. A subgroup consisting of 12 patients on regular prophylaxis throughout the studied years was separately evaluated. Data assessed included annual factor consumption (IU/kg) and annual cost for the years studied. The prices for factor concentrates were obtained from the Greek National Organization for Medicines. Changes in patients’ family working status and subsequent insurance coverage were also recorded.
Results
Mean age of patients was 11.3 year (range 2-19 years). The mean annual factor consumption did not significantly differ between the onset of crisis and the following years in both groups studied (i.e. total and regular prophylaxis patients). Similarly, the average annual cost per patient did not significantly change during the crisis years for either group. In specific, mean factor consumption for the whole group at starting and closing years was 334.167 ± 227.536 U/KG and 318.235 ± 105.92 U/KG, respectively, with respective mean annual costs 114,864 ± 82,097 and 108,989 ± 62,862 euros. For the regular prophylaxis group mean factor consumption for starting and closing years was 350.16± 268482 U/KG and 318.235 ± 105.92 U/KG, respectively, with mean annual costs 114,187 ± 97,772 and 134,61 ± 54,159 euros. With regards to employment and insurance ability, one patient lost coverage due to parents' unemployment. However, Social Security provided cost-free factor administration, enabling patient to continue his treatment. The only change recorded between crisis onset and following years was a significant increase in number of hospital visits required in order to have access to factor administration, as a result of limited amount of factor administered by the hospital at each visit for home treatment.
Conclusion
Although Greece has seriously suffered during the last years because of the economic crisis, provision for health has managed to survive - at least for hemophilia patients. Albeit, without some cost on the patients’ part…
Session topic: E-poster
Keyword(s): Children, Hemophilia A
{{ help_message }}
{{filter}}